Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report

Pathol Int. 2011 Jun;61(6):363-8. doi: 10.1111/j.1440-1827.2011.02662.x. Epub 2011 Mar 13.

Abstract

This report concerns a unique case of a composite lymphoma composed of T-lymphoblastic leukemia/lymphoma (T-LBL) and diffuse large B-cell lymphoma (DLBCL) in a 72-year-old woman with generalized lymphadenopathy, splenomegaly and ascites. Laboratory findings showed increased lactate dehydrogenase and soluble interleukin-2 receptor. The biopsy specimen showed replacement of the normal architecture of the lymph nodes by a tumor containing a dual cell population composed of large lymphocytes and medium-sized lymphocytes. Sheets of large lymphocytes often were punctuated by clusters of medium-sized lymphocytes. Flow cytometry and immunohistochemical analysis showed a composite lymphoma with both T-LBL and DLBCL. The T-LBL expressed CD1a, CD3, CD4, CD8, and terminal deoxynucleotidyl transferase. The DLBCL expressed CD19 and CD20, CD23, bcl-2, bcl-6, MUM1 and immunoglobulin κ light chain. Polymerase chain reaction detected a monoclonal pattern of T-cell receptor γ and immunoglobulin heavy chain rearrangements in the same specimen. She received eight cycles of R-CHOP (rituximab+cyclophosphamide, doxorubicin, vincristine, prednisone) therapy and achieved complete remission. She has shown no signs of recurrence 20 months after the diagnosis. We describe here a very unusual and, to the best of our knowledge, an as yet never reported case of a primary composite lymphoma of T-LBL and DLBCL.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antigens, CD / metabolism
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Composite Lymphoma / blood
  • Composite Lymphoma / drug therapy
  • Composite Lymphoma / pathology*
  • Cyclophosphamide / therapeutic use
  • DNA Nucleotidylexotransferase / metabolism
  • DNA, Neoplasm / genetics
  • Doxorubicin / therapeutic use
  • Female
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • L-Lactate Dehydrogenase / metabolism
  • Lymphoma, Large B-Cell, Diffuse / blood
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Prednisone / therapeutic use
  • Receptors, Interleukin-2 / metabolism
  • Rituximab
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • DNA, Neoplasm
  • Receptors, Interleukin-2
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • L-Lactate Dehydrogenase
  • DNA Nucleotidylexotransferase
  • Prednisone

Supplementary concepts

  • CHOP protocol